Work

343TiP Pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer: Methodology of phase 3 randomized trial

Year: 2015

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdv527.30

Authors: J.-P. Machiels, S.W. Shin, E. Cohen, K. Harrington, B. Burtness, C. Gause, A. Swift, R. Swaby, C. Le Tourneau

Institutions: Cliniques Universitaires Saint-Luc, Korea University, Korea University Medical Center, University of California San Diego, Moores Cancer Center, Institute of Cancer Research, Yale Cancer Center, Yale University, Merck & Co., Inc., Rahway, NJ, USA (United States), Institut Curie

Language: English

Topic: Head and Neck Cancer Studies

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4253278919

FWCI: 0.3

Cites:

Cited by: 1

Related to: 10